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Available online 10 November 2016Aging is the key risk factor for Alzheimer's disease (AD). In addition, the amyloid-beta (Aβ) peptide is considered
a critical neurotoxic agent in AD pathology. However, the connection between these factors is unclear.We aimed
to provide an extensive characterization of the gene expression proﬁles of the amyloidosis APP23 model for AD
and control mice and to evaluate the effect of aging on these proﬁles. We also correlated our ﬁndings to changes
in soluble Aβ-levels and other pathological and symptomatic features of themodel.We observed a clear biphasic
expression proﬁle. The ﬁrst phase displayed a maturation proﬁle, which resembled features found in young car-
riers of familial ADmutations. The second phase reﬂected aging processes and showed similarities to the progres-
sion of human AD pathology. During this phase, themodel displayed a clear upregulation of microglial activation
and lysosomal pathways and downregulation of neuron differentiation and axon guidance pathways. Interest-
ingly, the changes in expressionwere all correlated to aging in general, but appearedmore extensive/accelerated
in APP23 mice.







Dementia is considered to be one of themost burdensome disorders
of later life. Aging is believed to be themain risk factor for dementia. No
other disorders display higher age dependence than dementia [1].
Alzheimer's disease (AD) is believed to be the main cause of dementia.
However, the proportion of cases caused by AD varies based on gender,
age and whether mixed types of dementia are considered a separate
subtype. Speciﬁcally, AD accounts for about 70% of all dementia at
later age in women. In men, AD causes about 38% of all dementia be-
tween 65 and 69, but this percentage climbs progressively to 80% at
90 years and older [2]. AD is a neurodegenerative disorder causing pro-
gressive cognitive impairment and behavioural disturbances. The brain
of AD patients is neuropathologically characterized by neuronal loss,
gliosis, dystrophic neurites, amyloid plaques and neuroﬁbrillary tangles
of hyperphosphorylated tau [3]. Genetically, AD can be categorized into
two distinct types: sporadic AD (SAD) and familial AD (FAD). SAD isry and Behavior, Institute Born-
ersiteitsplein 1, 2610, Wilrijk,
n Dam).considered to be a polygenic/multifactorial disorder and accounts for
over 99% of all AD. While no clear genetic cause has been found for
SAD, multiple genetic risk factors have been identiﬁed [4]. FAD, on the
other hand, is caused bymutations inherited in an autosomal dominant
fashion and accounts for b1% of all AD. FAD patients tend to display a
relatively earlier age of onset, between 35 and 65 years of age, when
compared to SAD. As a result, FAD is also often termed early-onset AD
[5]. However, the majority of early-onset cases (i.e. onset before the
age of 65) do not carry an FAD mutation and are, in fact, SAD cases. All
known FAD mutations are located in one of three genes: the presenilin
1 (PSEN1), presenilin 2 (PSEN2) or the amyloid precursor protein (APP)
gene [6–11]. Interestingly, all these genes play a crucial role in the pro-
duction of the amyloid-beta (Aβ) peptide, the main component of the
aforementioned amyloid plaques typically found in the brains of AD pa-
tients. The Aβ peptide has been found to vary in length between 37 and
43 amino acids. Themost commonly produced variant is 40 amino acids
in length (Aβ1–40), but the Aβ variant with 42 amino acids (Aβ1–42) is
believed to be more prone to aggregation and, therefore, more neuro-
toxic [12–15]. FAD mutations have been shown to result in either
an overall increase in Aβ production or a proportional shift towards
the production of Aβ1–42 [16–22]. Based on the genetic evidence, the
neuropathological lesions and biochemical research conﬁrming the
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mulated, which states that the Aβ peptide is a key factor in AD patholo-
gy [23,24]. Given this potentially central role of Aβ and the strong
correlation between AD and aging, we decided to investigate the inter-
action between soluble Aβ levels and age in a transgenic mouse AD
model [25]. Due to the inherent difﬁculties in studying brain disorders
and the prolonged time course of AD pathology in humans, transgenic
mouse models have proven an invaluable tool in AD research. The
APP23 mouse model carries a construct containing the human APP751
gene with the Swedish double mutation (K670N/M671L) [26]. This is
a known FADmutation and results in an overall increase of Aβ produc-
tion [22]. The model presents with neuropathological lesions, cognitive
deﬁcits and behavioural alterations in an age-dependent fashion, simi-
lar to humanADpathology [27,28]. Recently, we uncovered that the sol-
uble Aβ levels in APP23mice follow a distinct pattern over the course of
their life. After an initial increase in the soluble overall Aβ and Aβ1–40
levels at 1.5 months, the soluble Aβ levels remained stable until past
12 months of age. Only at the late ages of 18 and 24 months, could an
additional, gradual increase in Aβ levels be detected. We also demon-
strated that rises in overall Aβ and Aβ1–40 levels are usually preceded
by a rise in Aβ1–42 levels. As the rise in Aβ levels at young age coincided
with an increase in APP levels, this risemight simply reﬂect an evolution
in Aβ production associated with brain maturation. However, we were
unable to link the Aβ alterations at older ages to changes in the levels
of proteins involved in the production of Aβ [25]. Of course, the activity
of Aβ producing proteins may be altered by the aging process. Another
explanationmight be that the rise in Aβ levels at old age is the result of a
reduction in Aβ clearance [29–35]. We, therefore, decided to use RNA
sequencing to map other age-related changes in the expression proﬁle
of our mouse model. In our current study, we used differential expres-
sion analysis and weighted gene co-expression network analysis
(WGCNA) to explore age-related and genotype-related changes in the
APP23 mice. We also examined how these changes correlate to soluble
Aβ levels. Finally, we also discuss how these ﬁndings relate to the path-
ological changes and AD-like symptoms observed at various ages in the
APP23 model.
2. Materials and methods
2.1. Animals
Threemale heterozygous (HET) APP23micewere included in all age
groups for the RNA sequencing analysis. An equal number of male wild-
type (WT) littermates were included as a control group. Genotypes
were determined through PCR. All mice were bred within our facilities
on a C57Bl/6J background and group-housed in standard mouse cages
under conventional laboratory conditions with a 12:12 h light–dark
cycle (light on at 8:00 AM, light off at 8:00 PM), constant room temper-
ature (22 ± 2 °C), humidity level (55 ± 5%), and food and water avail-
able ad libitum. Based on the timing of the previously observed changes
in the soluble Aβ levels [25], four age groups were selected: 1.5, 6, 18
and 24 months. Experiments were conducted in accordance with the
European Directive (2010/63/EU) on the protection of animals used
for experimental and other scientiﬁc purposes, and the Animal Ethics
Committee of the University of Antwerp approved all procedures.
2.2. Brain tissue collection
Animals were euthanized at the desired age through cervical
dislocation. The brain was harvested and dissected on ice into three
parts: two hemi-forebrains and the cerebellum (the olfactory bulbs
were discarded). After dissection the brains were immediately stored
at−80 °C until use. One hemi-forebrainwas used for protein extraction
and subsequent biochemical analysis. The other hemi-forebrain was
used for RNA isolation and sequencing.2.3. Protein extraction and ELISA
Proteins were extracted from the brain tissue and the Aβ levels
(Aβ1–x, Aβ1–40 and Aβ1–x) were determined through ELISA analysis ac-
cording to the protocols previously described [25].
2.4. RNA isolation and sequencing
The frozen hemi-forebrains were lysed in QIAzol (Qiagen),
followed by total RNA isolation using the RNeasy Lipid Tissue
Mini Kit (Qiagen, 74804). The quality and concentration of the
RNAwas determined using the 2100 Bioanalyzer (Agilent, Amstelveen,
The Netherlands) with the Agilent RNA 6000 Nano Kit and 3 high
quality samples (RIN N 7.5) per condition were included for
sequencing.
Sequence libraries were generated with the TruSeq RNA sample
prep kit V2 (Illumina) using the Sciclone NGS liquid handler (Perkin
Elmer). To multiplex the samples in two pools, 24 unique barcoded
adapters (Illumina) were applied. The generated cDNA libraries were
sequenced on an Illumina HiSeq2500 using default parameters (single
read 50 base pairs in High Output modus).
2.5. Bioinformatic data preprocessing
The data was inspected with FASTQC (v0.10.1) [Babraham institute,
available online at: http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/] and trimmed when necessary with FASTX trimmer [Hannon
Lab, available online at: http://hannonlab.cshl.edu/fastx_toolkit/]. Align-
mentwas performedwith STAR (2.3.1 l) [36] with 2mismatches allowed
to the ensemble reference genome version 37 of the 1000Genome
project. Between 10 and 16 million high-quality uniquely aligned
reads were obtained per sample. Data was quantiﬁed with HT-Seq
count (0.5.4) [37]. The complete dataset was uploaded to the GEO
repository of the National Center for Biotechnology Information
(NCBI) and are accessible through GEO Series accession number:
GSE80465.
2.6. Differential genes expression analysis
The raw count data were preprocessed with the use of the program-
ming languageR (3.2.2) [R Core Team, 2015, available online at:www.r-
project.org], the program RStudio (0.99.484) [RStudio Team, 2015,
available online at: http://www.rstudio.com/] and the EdgeR package
(3.12) [38]. Genes that contained a count per million (CPM) value N1
in at least two samples were kept resulting in 15,728 genes that were
used in the differential analysis. Differential expression of the data was
performed by pairwise comparisons, as well as a generalized linear
model with genotype and age asmain variables and a genotype ∗ age in-
teraction variable. The generalized linear model (GLM) approach was
applied to both genotypes of the 1.5 and 6 month old animals (matura-
tion design) and to both genotypes of the 6, 18 and 24month old animals
(aging design). In the aging design, age was used as a quantitative
variable. The “false discovery rate” (FDR)methodwas used to statistically
correct for multiple comparisons.
2.7. Weighted gene co-expression network analysis (WGCNA)
WGCNA (1.48) [39,40] was applied to identifymodules of highly co-
expressed genes. Genes ofwhich themean CPMexpression valueswere
below the 25% quartile where removed, resulting in a co-expression
matrix of 11,796 genes. A signed network was generated with a beta
value of 10, and after clustering of the genes in modules only modules
of 100 genes or morewere used for downstream analysis. Highly corre-
lating modules were merged with the WGCNA MergeCloseModules
function with a cutoff of 0.25. ModuleTrait correlations were calculated
between the modules and 5 predictive variables: Genotype, Age,
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variables contained the various ages of the animals for that particular
genotype, while the other genotype was maintained at 1.5 months, in
order to identify genotype-speciﬁc age-related modules. In addition,
the ModuleTrait relationships between the modules and the observed,
soluble Aβ levels was also determined.
To functionally annotate the modules and the differentially
expressed gene lists DAVID was used [41,42]. In addition, the WGCNA
userlistEnrichment function was applied to functionally annotate the
modules [43]. This function contains an extensive CNS cell type-
speciﬁc gene expression proﬁles.Fig. 1. Results of differential gene expression analysis. A) Multi-dimensional scaling plot display
and aging, are indicated by a red and green circle, respectively. B) Venn diagrams displaying the
variables in the two generalized linear model designs. C) Heatmaps depicting the top differ
interaction effect for the maturation and aging designs. These top genes are categorized acc
heterozygote; WT, wild-type; m, months.3. Results
3.1. The APP23 transcriptome proﬁle
To determine the effect of age and mutated APP overexpression on
gene expression levels in the central nervous system, Illumina RNA-
sequencing was applied to one hemi-forebrain of APP23 and WT ani-
mals aged 1.5, 6, 18 and 24months. The relationships between the sam-
ples and conditions were visualized in a multi-dimensional scaling
(MDS) plot (Fig. 1A). The MDS plot conﬁrmed that the different biolog-
ical triplicates cluster closely together.ing the results for the various age and genotype groups. The two main trends, maturation
numbers of differentially expressed genes grouped according to their associationwith the
entially-expressed genes for the main effects of aging, genotype, and the age-genotype
ording to unique and signiﬁcant associations with main variables. Abbreviations: HET,
Table 2
# Differentially expressed genes between 2 age groups of the same genotype.
Ages WT HET
#Total #Up #Down #Total #Up #Down
2 M compared to 6 M 1277 708 569 731 469 262
6 M compared to 18 M 50 19 31 280 42 238
18 M compared to
24 M
398 168 230 858 439 419
Abbreviations: HET, heterozygous; WT, wild-type; M, months.
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two circles on the plot. The youngestWT andHET groups cluster togeth-
er at the lower left corner, whereas the 6-month-old WT and HET
groups are clustered in the top left-hand corner. This initial upward
trend appears to occur speciﬁcally between the two youngest age
groups and was categorized as the maturation proﬁle (the red circle).
The oldest age groups, on the other hand, display a shift downward
and to the right. This trend, involving the 6-, 18- and 24-month age
groups, was classiﬁed as the aging proﬁle (the green circle). This aging
effect ismost pronounced in the APP23 group, resulting in an increasing
divergence between the HET and WT animals.
The differential expression of genes was initially assessed by a sim-
ple pairwise comparison between the various experimental groups.
The number of genes that signiﬁcantly differ in expression between
two particular experimental groups (FDR b 0.05) are reported in
Tables 1 and 2. Interestingly, these comparisons showed that at
6 months of age the only two differentially expressed genes are APP
and Thy1, both of which are components of the construct introduced
in the APP23 model. The expression level of both genes appears to in-
crease in HET animals at the earliest ages, before levelling out at a
later age. In accordance with what we observed in the MDS-plot, the
number of genes differentially expressed between WT and HET rises
with increasing age.Within a given genotype groupmost of the expres-
sion changes appear to occur early or late in life.
3.2. The generalized linear model analysis
TheGLMdesignswere used for further analysis of the differential ex-
pression. Based on the previously observed proﬁles, two GLM designs
were developed: a maturation design containing APP23 and WT mice
of 1.5 (juvenile) and 6 months (adult) of age and an aging design that
contained APP23 and WT mice of 6, 18 and 24 months. The 6-month-
old group is considered a turning point and was included in both de-
signs as a reference group (when the differences in expression between
APP23 and WT mice are minimal and restricted to the introduced con-
struct). The designs examine which gene expression changes are due
to the effect of aging, the effect of genotype or an interaction between
the two.
For the maturation design, 40 genes were differentially expressed
between genotypes, 1315 genes differed between 1.5 and 6 month old
mice, and 16 genes were signiﬁcantly associated with the interaction
effect (FDR b 0.05) (Suppl. Tables 1–3). Several genes were also
overlapping between these effects (Fig. 1B); for example, 9 genes
were signiﬁcantly associated with age, genotype and the interaction ef-
fect. Together, these results indicate that changes in gene expression
levels were most strongly affected by maturation, and that the differ-
ence between genotypes, and the difference in the maturation proﬁle
between both genotypes, were relatively minor.
Similarly, a GLM approach was applied to the aging design contain-
ing the samples from the 6-, 18- and 24-month-old mice. The expres-
sion of 28 genes was affected by genotype, 311 genes were affected by
age, and84genes associatedwith the interaction effect (Suppl. Tables 4–
6). These ﬁndings indicate that the effect of age in the aging design is
much less pronounced than in the maturation design (311 versus
1315 affected genes). Interestingly, the interaction between age and
genotype effect is more pronounced for the aging design (84 versusTable 1
# Differentially expressed genes in HET animals compared to WT animals.
Age #Total #Upregulated #Downregulated
2 M 8 6 2
6 M 2 2 –
18 M 189 166 23
24 M 422 215 207
Abbreviations: HET, heterozygous; WT, wild-type; M, months.16 genes). This again suggests that in APP23 samples, gene expression
levels become increasingly different from control littermates with
progressive age.
Heatmaps were generated that depict the principal differentially-
expressed genes for the main effects of aging, genotype, and the age-
genotype interaction effect for the maturation and aging designs
(Fig. 1C). These top genes were subsequently categorized according to
unique and signiﬁcant associations with main variable of age (yellow),
genotype (green) or interaction effect (blue) or to a combination of
these; age and genotype (light green), age and interaction (light
blue); genotype and interaction (dark green), or all three effects (light
bluegreen), in analogy to the categories visualized in the Venn diagrams
in Fig. 1B.
As expected, the category genotype-unique for both the maturation
and aging designs contained the APP gene, the gene responsible for
inducing the pathology in APP23 mice. Interestingly, the Thy1 gene,
which drives the expression of the APP gene in the construct, was also
found in the genotype-unique category of the aging design. In the mat-
uration design, however, an interaction effect could be observed in ad-
dition to the genotype effect, indicating that the Thy1 expression
changes with age during the maturation stage. For the aging design,
Cd68 was present in the interaction-unique category. Cd68, a marker
for activated microglia, was increased in expression in aged APP23
mice speciﬁcally. Similarly, Gfap, a marker of activated astrocytes, was
present in the combined interaction and age effects, suggesting age-
related astrocytosis which was more pronounced in APP23 mice. In ad-
dition, several microglia genes were detected in the main effect of the
age-unique category, such as Cd11c,Mmp12, Clec7a, H2-Q5, H2-Q6 and
H2-Q7. Moreover, Lgals3bpwas observed in the combined main effects
and interaction effect category.
Given this study's focus on aging effects, functional enrichment
analysis was performed on the aging design for genes signiﬁcantly
associated with themain effect of age and the age-genotype interaction
effect (Table 3). The top GO term that was enriched for the age effect
was ‘Immune Response’ (Benjamini p = 4.3E−19), and the top GO
term for the interaction effect was ‘Acute inﬂammatory response’
(Benjamini p = 2.4E−03). These observations are in line with the
heatmap, suggesting that there is an age-related increase in inﬂamma-
tory genes, whichwasmore pronounced in APP23mice. KEGG pathway
analysis revealed the complement and coagulation pathway (Benjamini
p = 5.5E−03) and the lysosome pathway (Benjamini p = 4.5E−05) as
top results for the main effect of age and the age-genotype interaction
effect, respectively.
3.3. Weighted gene co-expression network analysis (WGCNA)
In addition to a differential expression analysis, a WGCNA-based
clustering analysis was performed to detect groups of co-expressed
genes that differed between conditions. A dendrogram was generated
with branches of highly correlating genes that were identiﬁed as mod-
ules (Fig. 2A). The Module Eigengene (ME), the ﬁrst principal compo-
nent of the eight identiﬁed modules, was subsequently correlated to
predictive variables to determine the expression of the modules
(Fig. 2B). Five predictive variables were included in this analysis: geno-
type, age, maturation, and two interaction variables APP23-Aging and
Table 3
Results of the functional annotation of differentially expressed genes using DAVID.
GO Benjamini KEGG Benjamini
Main effect age (aging design) Immune response 4.3E−19 Complement and coagulation cascades 5.5E−03
Immune effector process 1.6E−10 Antigen processing and presentation 7.3E−03
Leukocyte-mediated immunity 9.5E−08 Systemic lupus erythematosus 2.5E−02
Interaction effect (aging design) Acute inﬂammatory response 2.4E−03 Lysosome 4.5E−05
B-cell mediated immunity 3.4E−03 Complement and coagulation cascades 4.0E−02
Immunoglobulin-mediated immune response 3.9E−03 Systemic lupus erythematosus 8.3E−02
Fig. 2. Results of the weighted gene co-expression network analysis. A) Cluster dendrogram depicting the identiﬁed modules of highly correlating genes. B) Heatmap displaying the
correlations (r- and p-values) between the gene modules and the ﬁve predictive variables. C) Boxplot depicting the Module Eigengene expression levels of the ‘darkblue’ module for
the various experimental groups. D) Boxplot depicting theModule Eigengene expression levels of the orangemodule for the various experimental groups. E) Boxplot depicting theModule
Eigengene expression levels of the ‘yellow’module for the various experimental groups. Abbreviations: HET, heterozygote; WT, wild-type; ME, Module Eigengene.
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with one or more of these variables were: ‘darkblue’, ‘lightgreen’,
‘lightblue’, ‘orange’ and ‘yellow’. No modules signiﬁcantly associated
with genotype or the interaction variable WT-Aging.
The ‘lightgreen’ module signiﬁcantly and positively correlated with
the ‘maturation’ variable (R = 0.81; p = 2E−06) suggesting that this
group of genes was highly expressed during maturation compared to
adult mice (Fig. 2B). It is enriched for an ‘astrocytes’ gene set from
[109] (Benjamini p= 2.8E−18) and the ‘Blood vessel development’ GO
category (Benjamini p=2.4E−08) (Suppl. Table 7). The ‘lightblue’mod-
ule negatively correlated with the ‘maturation’ variable (R =−0.92;
p = 3E−10) and positively with the ‘age’ variable (R = 0.74; p =
3E−05), suggesting an age-related increase (Fig. 2B). It is enriched for
the ‘Calcium signalling’ KEGG pathway (Benjamini p = 2.1E−02)
(Suppl. Table 7). Neither the ‘lightgreen’, nor the ‘lightblue’ module
displayed any effects related to genotype.
The ‘orange’ module correlated negatively to the ‘APP23-aging’
interaction variable (R = −0.63; p = 0.0001) (Fig. 2B). The ‘orange’
ME only showed a profound down-regulation in 24-month-old APP23
mice (Fig. 2D). This module is enriched for a ‘transcription’ GO and
a ‘synaptic transcriptome’ gene set from Cajigas and co-workers
(Benjamini p = 1.9E−07) (Table 4) [44], suggesting that synaptic
composition is altered in APP23 mice aged 24 months. This is the only
module that does not show an overall aging effect in addition to an in-
teraction effect.
The ‘darkblue’module correlated positivelywith the ‘age’ (R=0.77;
p = 1E−05) and ‘APP23-Aging’ (R = 0.79; p = 5E−06) variables,
suggesting age-related alterations in gene expression, which are
modiﬁed further in APP23mice (Fig. 2B). TheME of the ‘darkblue’mod-
ule was depicted as a boxplot (Fig. 2C), and showed an age-related in-
crease, which was more pronounced or potentially expedited in the
APP23 mice. This module was enriched for ‘immune response’ GO-
term (Benjamini p= 9.5E−28), ‘Lysosome’ KEGG pathway (Benjamini
p = 6.1E−04), and ‘microglia’ gene set of userlistEnrichment (UE)
(Benjamini p = 1.2E−24) (Table 4). These observations are in line
with the results from the GLM analysis. A variety of cathepsins, which
are involved in lysosomal protein degradation, are prominently repre-
sented in the module. Interestingly, this module also contains most of
the SAD genetic risk factors that have been linked to microglial activa-
tion, like Triggering Receptor Expressed on Myeloid cells2 (Trem2)
and its co-receptor TYRO Protein Tyrosine Kinase Binding Protein
(Tyrobp), Cd33, ATP-binding cassette transporter A 7 (Abca7), Inositol
Polyphosphate-5-Phosphatase (Inpp5d) and apolipoprotein E (Apoe).Table 4




Darkblue 2375 GO Immune response 9.5E−28




Immune system reactome 4.3E−12
Orange 982 GO Transcription 1.5E−02
Protein amino acid dephosphorylation 6.7E−02
UE Synaptic transcriptome [44] 1.9E−07
Yellow 2167 GO Neuron differentiation 6.0E−03
Transmission of nerve impulse 2.9E−02
KEGG Pathways in cancer 7.7E−05
Axon guidance 4.1E−03
Abbreviation: WGCNA, weighted gene co-expression network analysis; UE,
userlistEnrichment.Complement receptor 1 (Cr1), another risk factor that has also been
linked to the immune system, was not found in this module, but several
other subcomponents of the ﬁrst component of the complement system
were (i.e. C1qa, C1qb, C1qc and C1ra).
The ‘yellow’module positively correlated to ‘maturation’ (R=0.81;
p = 2E−06), and negatively to ‘age’ (R = −0.86; p = 8E−08), and
‘APP23-aging’ (R = −0.63; p = 0.001) variables (Fig. 2B). The ME
of the ‘yellow’ module was highest in immature animals with age-
related decrease, which was most prominent in the APP23 mice
(Fig. 2E). This module is, among others, enriched for ‘neuron differenti-
ation’ — GO (Benjamini p = 6.0E−03) and ‘axon guidance’ — KEGG
(Benjamini p = 4.1E−03) gene sets (Table 4). This suggested an age-
related decrease in axonal guidance and neuronal differentiation signal-
ling genes, whichwasmost pronounced in APP23mice. Fermitin Family
Member 2 (Fermt2), a SAD risk gene linked to cytoskeletal function and
axonal transport, was also found in this module.
Finally, we explored the relationship between theME of these mod-
ules and the brain Aβ levels that weremeasured in these animals. Inter-
estingly, the strongest signiﬁcant correlations were observed with the
overall Aβ1–x levels (Suppl. Fig. 1). The ‘darkblue’ and ‘orange’ module,
respectively, displayed the highest positive (R = 0.69; p = 2E−04)
and negative correlation (R = −0.66; p = 4E−04) to the Aβ1–x
levels. In addition, these modules also displayed a similar, but weaker
correlation to the Aβ1–40 levels (‘darkblue’: R=0.6; p=0.002, ‘orange’:
R = −0.58; p = 0.003). Surprisingly, a positive correlation was
also found between the Aβ1–x levels and the ‘darkgreen’ module
(R = 0.60; p = 0.002). This module did not relate to our other vari-
ables and appears to be enriched for ‘DNA metabolic processes’ and
‘DNA repair’ GO gene sets (Suppl. Table 7). Finally, the ‘yellow’ module
also showed a negative correlation with the Aβ1–x levels (R=−0.59;
p=0.002). The correlations between themodules and the Aβ1–42 levels
failed to reach the signiﬁcance level (p b 0.005).
4. Discussion
The goal of this study was to examine the role of aging and age-
related changes in gene expression in the APP23 mouse model for AD.
Overall, our study revealed a very distinct pattern in the gene expres-
sion proﬁle. We observed an initial, maturation stage at the youngest
ages with a large amount of changes in gene expression. Notably, our
GLM analysis showed that the vast majority of these changes are age-
related and only ~3% of the changes are linked to the genotype. More-
over, the WGCNA analysis also revealed three modules that correlated
with maturation, but none of these modules appeared to be affected
by the genotype variable. In fact, given that these modules have func-
tional annotations like ‘neuron differentiation’, ‘axon guidance’ and
‘blood vessel development’, their involvement in this maturation
phase is quite logical. Actually, during the maturation stage, the differ-
ences between WT and HET appear to diminish until at 6 months the
only signiﬁcantly differentially expressed genes between both groups
are the APP and Thy1-gene of the transgenic construct. Our analyses
show that the expression level of both these genes increases during
the initial maturation stage and reaches an elevated, steady state at
later ages. In a previous study, we also observed an increase in the pro-
tein levels of APP between the age of 1.5 and 6months after which they
levelled out [25]. These ﬁndings seem to conﬁrm our previous hypoth-
esis that a further maturation of the brain takes place in juvenile
APP23 mice which may be the cause of the initial rise in soluble Aβ
levels observed in the model.
The existence of this maturation stage does, however, raise some in-
teresting issues about the interpretation of ﬁndings at these young ages.
For instance, young APP23 animals up to the age of 8months have been
shown to have 10–15% more neurons compared to controls and older
APP23 animals [45,46]. This augmented volume of speciﬁc brain regions
has also been observed in young human FAD carriers and has been
linked to differences in functional connectivity [47,48]. It is unclear,
Table 5
Differences observed in heterozygous APP23 mice compared to wild-type control animals.




Dense core plaques 3 m, 6 m, 8 m, 12 m, 19 m, 24 m, 25 m 6 m Progressive; plaques increase and spread 26, 27, 64
Diffuse plaques 14–18 m 14 m Limited, speciﬁc brain regions, most common
with high plaque burden, b10% of plaque total
46
Cerebral amyloid angiopathy 8 m, 14–21 m, 19 m, 27 m 14 m Progressive; Starts in leptomeningeal vessels 69, 70
Hyperphosphorylated tau 6 m,9 m,12 m,15 m,18 m, 24 m 6 m Progressive; occurs parallel with plaque deposition 26, 27
Dystrophic neurites & axonal sprouting 6 m,9 m,12 m,15 m,18 m, 24 m 6 m Progressive; occurs around dense core plaques 26, 27
Inﬂammatory response 4–9 m, 6 m, 9 m, 12 m, 14–18 m,
15 m, 15–20 m, 16 m,18 m, 20 m 24 m
6 m Progressive; occurs around dense core plaques 26, 27, 61, 63, 75
Higher number of neocortical neurons 2 m, 8 m, 14–18 m, 27 m 2 m Difference disappears with age. No difference
past 14–18 m. Correlates with plaque load.
45, 46
Neuronal loss in CA1 14–18 m 14 m Increases; correlates with plaque load 46
Disrupted synaptic function (CA1) 3 m, 6 m, 9 m, 12 m, 18 m, 24 m 12 m Largest at 18 m; no detectable difference at 24 m 71
Altered neurotransmitter levels 7–8 m 7–8 m Differences in cholinergic, noradrenergic, serotonergic
systems + glycine and inhibitory amino acid levels
67
Deterioration of the cholinergic system 6 m, 15 m, 24 m 15 m Decrease in cholinergic enzyme activity and ﬁber length 68
Cognitive deﬁcits:
Reduced MWM performance 6–8w, 3 m, 6 m, 16 m, 18 m, 24 m, 25 m 3 m No change observed beyond 3 m until 25 m 53, 56, 57, 59
Passive avoidance learning diminished 6–8w, 3 m, 6 m, 18 m 25 m 25 m NA 53, 57
Slower learning in plus shaped water maze 6 m 6 m NA 54
Impeded complex maze performance 10 m 10 m NA 58
Impaired Barnes maze learning 12 m 12 m NA 55
Behavioural changes:
Altered cage activity proﬁle 3 m, 6 m, 12 m 6 m Changes more pronounced at 12 m 72
Hyperactivity 6–8w, 3 m, 6 m 6–8w No evolution observed 53
Increased aggression 6 m, 12 m 6 m No evolution observed 73
Abbreviation: m, months; MWM, Morris water maze; NA, not available; w, weeks.
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mental difference or a part of AD pathology. Both APP and presenilins
have been shown to play a part in neuronal development under normal
physiological circumstances and mutations in these genes may affect
their ability to optimally perform their normal function [49–52]. This
may, however, be unrelated to other pathological effects, like Aβ toxic-
ity for example. The ﬁrst cognitive deﬁcits in APP23mice have been ob-
served at the age of three months [53] (Table 5). In the light of these
discoveries, we have to ask ourselves if this diminished performance
in the Morris water maze is an early, pathological deterioration of
higher order brain function, comparable to the mild deﬁcits observed
in the earliest disease stages, or is it in fact the result of a deviation in
brain development. The age at which cognitive deﬁcits areﬁrst detected
in the APP23model has proven to be highly dependent upon the exper-
imental set-up used in the testing. In general, however, complex cogni-
tive tasks do seem to be impaired earlier than simpler memory tasks,
similar to the progression of cognitive decline in human AD patients
[53–59]. In the end, the APP23model does appear tomimic the progres-
sive cognitive deterioration of the human condition, but the earliest ob-
served cognitive deﬁcits may not necessarily reﬂect the ﬁrst observable
cognitive deﬁcits in humans and should, therefore, be interpreted with
caution. While these changes in young APP23 mice seem to correlate
well with the situation in young human FAD patients, they may relate
poorly to SAD and could seriously impact the potential extrapolation
of research results.
Nevertheless, in addition to the maturation phase of the gene
expression proﬁle, we also observed an aging phase. Starting at
6 months of age with minimal gene expression differences between WT
andHETanimals,wedetermined an ever increasingnumber of alterations
in gene expression and an increasing divergence between both genotypes
with increasing age. At 6 months of age, the ﬁrst sporadic, compact
plaques can be observed in theAPP23model. These plaques are accompa-
nied by local changes, like activated microglia, hypertrophic astrocytes,
axonal sprouting and dystrophic neurites [26,27,60–64] (Table 5). In
human pathology these ﬁrst alterations are believed to occur during the
preclinical stage, before the onset of symptoms [65]. The average age ofonset for carriers of an APP mutation in humans is just under 50 years
of age [5]. In C57BL/6J mice the equivalent age for this human age is esti-
mated at ~14months. The human age equivalent formice aged 6months
is believed to be 30 years [66]. Based on the humanequivalent ages, the 6-
month-old mice would indeed be expected to correspond with humans
in the presymptomatic stage. Unlike humans in this presymptomatic
stage, cognitive deﬁcits have been observed in APP23 mice at 6 months
[53,57]. However, to date there is no other experimental evidence to sup-
port that this cognitive deﬁcit has progressed beyond the deﬁcit that was
detected at 3months during thepreviously discussedmaturation stage. In
fact, the only additional worsening of cognitive symptoms in APP23mice
has been observed at the late age of 25 months in a small Morris water
maze and the passive avoidance test [57] (Table 5). Similarly, deviations
in the neurotransmitter systems were found in APP23 mice at the age of
6 months compared to WT littermates [67]. However, these alterations
were again not shown to progressively worsen over time. One study did
note a progressive deterioration of the cholinergic system, but these
changes were reported after 6 months. They reported minor changes at
15 months that became more extensive at 24 months [68] (Table 5).
Other pathological features, like hippocampal neuronal loss and vascular
amyloid deposition, have also been reported at 14 months and were
shown to exacerbate at later ages [45,46,69,70] (Table 5). Basic synaptic
function is reportedlymildly altered at 12months of age andmore exten-
sivelymodiﬁed at 18months in theAPP23model [71]. At 6months of age,
the spontaneous home cage locomotor activity proﬁle of APP23micewas
found to display minor differences compared to the proﬁle of wild-type
controls, and these differences became more pronounced at 12 months
[72]. Other behavioural disturbances in activity and aggression have also
been reported, even before age 6 months, but no progression of these
symptoms has been documented [53,73] (Table 5). Taken together,
these ﬁndings appear to conﬁrm the progression of AD-like pathology
during the aging stage in the APP23model. The timing of the pathological
features during this stage also seems tomatch the timing of the pathology
in human FAD patients.
Our WGCNA analysis revealed three modules that display clear
changes in gene expression during the aging stage: the ‘darkblue’,
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plays gene expression changes that are solely due to genotype effects.
All of the observed variations in gene expression do correlate to aging.
In fact, the ‘darkblue’ and ‘yellow’ modules both exhibit an aging effect
independent of genotype, indicating that thesemodules are also altered
with aging inWT animals. However, the alterations of these modules in
APP23mice appear to precede or exceed the changes in theWT animals.
At 18 months, the expression levels of the ‘darkblue’ and ‘yellow’mod-
ules differ signiﬁcantly in APP23 compared to agematched controls and
younger APP23 mice. These changes become even more prominent at
24 months. At this age, modiﬁcations in these modules can also be
observed in WT animals. The changes in expression in the APP23 mice
appear to follow the same temporal pattern as the one previously ob-
served for the soluble Aβ1–42 levels [25]. These similarities are, however,
not reﬂected in our correlation analysis of the soluble Aβ levels and the
ME of these modules. Our correlation analysis seems to pick up the
more prominent alterations at 24 months, but may lack sufﬁcient
power to detect the more modest effects at 18 months. Overall, the
aging stage of the APP23 model is characterized by accelerated age-
related alterations in gene expression and these accelerated changes ap-
pear associated with the rising levels of soluble Aβ and the appearance
of AD-like brain pathology.
The functional annotations of the three modiﬁed modules could,
therefore, provide valuable insights into the molecular processes in-
volved in the observed pathological changes. The ‘darkblue’module dis-
plays a clear association with immunological processes and enrichment
for the microglia gene set. This upregulation of immune-related genes
was also found in the GLM analysis and contain genes that previously
have been linked by our group to microglia priming [74]. Recently, our
group also microscopically conﬁrmed the presence of primed microglia
in the vicinity of plaques at 16 months of age in the APP23 model. At
24 months, priming could also be observed in non-plaque regions and
WT animals aswell [75]. These results are in linewith our current obser-
vations and with other studies reporting immune system activation in
the brains of both human AD patients and mouse models [76–81]. Sim-
ilar to ourﬁndings in oldWT animals, aging in humans has also been as-
sociated with immune system dysregulation (immunosenescence) and
chronic low-grade inﬂammation (inﬂammaging) [82–84]. Activated
microglia are involved in phagocytic clearance of pathogens and debris
and are responsible for the subsequent lysosomal degradation [74,80].
Our ‘darkblue’modulewas also signiﬁcantly enriched for the ‘lysosomal’
KEGG pathway and the SAD risk genes it contained have also been
linked to phagocytosis (as reviewed in [85]). Despite the apparent in-
crease in microglial activation, several studies have shown that these
microglia may be functionally impaired, displaying decreased mobility
and phagocytic capacity [86–90]. Phagocytosis and lysosomal degrada-
tion by proteases like cathepsins may play a role in Aβ clearance and
changes in these systems could therefore contribute to the observed ac-
cumulation of soluble Aβ [91–94]. At the moment, it is still unclear to
what extent the microglial activation occurs as compensatory immune
response to the increasing amyloid load or as a normal part of the
aging process which might contribute to the AD pathology.
The ‘yellow’module of our WGCNA analysis is functionally annotat-
ed for ‘neuron differentiation’ and the ‘axon guidance’ pathway. This
generally down-regulated module contains the genes of axonal guid-
ance cues like netrins, ephrins, slits, semaphorins and their receptors,
aswell as the genes of their downstreamproteins Ras, Pak and Rock. To-
gether, these elements of the ‘axon guidance’ pathway are responsible
for the regulation of the actin cytoskeleton. This regulatory mechanism
plays a crucial role in themorphogenesis of dendritic spines and regula-
tion of synaptic plasticity [95–97]. Moreover, Aβ and sAPPα have been
shown to interact with ephrin and semaphorin receptors, respectively
[98–101]. Aβ oligomers have also been shown to lead to aberrant Pak
activation and downstream modiﬁcation of the actin cytoskeleton and
dendritic spines [102,103]. These modiﬁcations in the regulation of
the actin cytoskeleton have been found both in AD mouse models andhumanADbrain [104–107]. Impairments in the axon guidance pathway
could explain the changes in basic synaptic function andmay lead to the
deterioration of cognition in the APP23 model at old age. Interestingly,
actin cytoskeleton regulation also plays a crucial role in phagocytosis
(as reviewed in [108]) and could provide a link between the changes
observed in neurons and microglia.
Finally, we also observed changes in the ‘orange’module, whichwas
annotated for the ‘synaptic transcriptome’ and transcription. Unlike the
‘yellow’ and ‘darkblue’ module, this module did not display an overall
aging effect. Based on the timing of the observed changes, it would ap-
pear that these changes in transcription at the synaptic level are a con-
sequence of earlier pathological effects. In this study, we performed a
global screening in the entire hemi-forebrain in accordance with our
previous experiments in APP23 mice [25]. Future research, could pro-
vide additional information about more modest changes, which might
have been masked or diluted with this approach, by performing
region- or cell type-speciﬁc analyses.
5. Conclusion
In conclusion, our study has shown a clear biphasic evolution in gene
expression changes in the APP23 model over time. While the initial,
maturation phase shares certain similarities with young FAD carriers,
it may not be representative for the pathological AD processes that
occur at later age in FAD and SAD patients. The second phase, however,
mimics several prominent features of the progressive AD pathology,
both in FAD and SAD. Our results show that aging is the crucial factor
during the second phase. The gene expression modules displaying the
most prominent alterations in APP23 mice, are also affected in WT ani-
mals, but the age-related changes appear accelerated/exacerbated in
APP23mice. These ﬁndings should be taken into account during the se-
lection of age groups for future research. The APP23 model does appear
to be a validmodel to further investigate the relationship between aging
and AD pathology. Microglial function and, perhaps more importantly,
cytoskeletal regulation pathways would appear to be themost interest-
ing targets for these future investigations.
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